Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guli capsule is a traditional Chinese medicine (TCM) developed by Guizhou Bailing Group Pharmaceutical Co Ltd for the treatment of various orthopedic and inflammatory joint conditions. It is primarily indicated for knee osteoarthritis, rheumatoid arthritis, and osteoporosis. The formulation has demonstrated the ability to suppress adjuvant-induced arthritis and reduce inflammatory swelling in preclinical studies. Clinically, it is utilized to alleviate joint pain and restore functional activity in patients. A Phase 4 clinical trial was conducted to evaluate its efficacy and safety in comparison to Kangguzengsheng capsules for knee osteoarthritis, focusing on its ability to improve symptoms and joint mobility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guli capsule (Guizhou Bailing Group Pharmaceutical Co., Ltd.).